SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, in collaboration with the laboratory of Violeta Serra, Ph.D., at Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, recently unveiled ...
Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) ...
SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma announced today that two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting held April 14-19, in Orlando, Florida, ...
Research uncovers how inhibiting interactions between cyclin A and cyclin B and their key binding partners, E2F and MYT1, selectively kills E2F-high tumor cells Circle Pharma’s oral first-in-class ...
Circle Pharma to Present Trials in Progress Poster on CID-078, a First-in-Class Cyclin A/B Inhibitor, at the ASCO 2025 Annual Meeting Circle Pharma, a clinical-stage biopharmaceutical company ...
Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, announced today that the first patient cohort has been ...
A 'pocket' on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct order. Cell division is key for life. Every organism -- from the smallest yeast ...
A "pocket" on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct order. Two studies by researchers at the University of Konstanz investigated ...
Researchers from Circle Pharma Inc. have presented preclinical data for CID-078, a novel orally bioavailable cyclin A/B Rxl macrocycle being developed for the treatment of patients with lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback